Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims are presented as label-evidence-based but are not supported by the provided FDA label excerpts, including specific study/journal details, named individual attribution, and reassurance/severity characterization about muscle effects and exercise that is not found in the cited sections.
Category Scores
Accurate Statements
Lipitor (atorvastatin) inhibits HMG-CoA reductase, the enzyme responsible for cholesterol synthesis.
Supported in 12.1 Mechanism of Action.
Lipitor lowers low-density lipoprotein (LDL) cholesterol.
Supported in 12.1 Mechanism of Action.
Unsupported Statements
A study in the Journal of Clinical Pharmacology reported significant declines in muscle strength and endurance in patients taking Lipitor compared with placebo.
No such specific study/journal findings are supported by the provided label excerpts.
The study concluded that Lipitor may have a negative impact on muscle function, particularly in individuals who engage in regular exercise.
Exercise-specific conclusion is not supported by the provided label excerpts.
Dr. Steven Nissen expressed concerns that statins can have a negative impact on muscle function, particularly in individuals who engage in regular physical activity.
Named individual/quote-based attribution is not supported by the provided label excerpts.
The patent for Lipitor expired in 2011, allowing generic versions of the medication to enter the market.
Patent/generic-entry timing is not supported by the provided label excerpts.
The effect of Lipitor on muscle function is generally mild and reversible.
No label support for a blanket mild/reversible characterization in the provided excerpts.
In most cases, patients taking Lipitor can continue to engage in regular exercise without experiencing significant adverse effects.
No label support for this reassurance about continuing exercise without significant adverse effects.
Lipitor may impair muscle function in individuals who engage in regular exercise.
Exercise-specific risk framing is not supported by the provided label excerpts.
Lipitor may increase the risk of muscle damage in individuals who engage in regular exercise.
Exercise-specific risk framing is not supported by the provided label excerpts.
Contradictions
Important Omissions
Label-consistent safety messaging for skeletal muscle effects (e.g., advising prompt reporting of unexplained muscle pain/tenderness/weakness and discontinuation if myopathy is diagnosed/suspected) is not reflected in the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported reassurance (mild/reversible effects; most patients can continue regular exercise without significant adverse effects) may reduce recognition of muscle-related adverse reactions that the label indicates require closer monitoring and prompt reporting. Several other unsupported evidence-specific claims (study details, named individual) add risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts, including specific journal study details, attribution to a named individual, and exercise-specific reassurance/severity claims about muscle effects.
Suggested Improvement
Limit muscle-related claims to what is supported in the provided label excerpt (e.g., risk of myopathy/rhabdomyolysis, risk factors such as renal impairment and interacting drugs, and patient reporting/discontinuation guidance). Remove unsupported journal/named-quote/patent timing claims and avoid blanket reassurance (mild/reversible; most patients can continue exercise without significant adverse effects) unless directly supported by the label.